Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme, ACMG Foundation Soliciting Applications for Clinical Genetics Fellowships


"The ability of medical genetics to adapt to the evolution of therapeutic approaches to genetic diseases will be critical to its sustained success," say Genzyme and the American College of Medical Genetics and Genomics Foundation in a new request for applications. The organizations are soliciting applications for their Clinical Genetics Fellowships in Biochemical Genetics program, which aims "to encourage the recruitment and training of clinicians for this purpose." Genzyme and the ACMG Foundation add that this "award program is designed to support the sustainable development of clinically interested and qualified clinical geneticists with expertise in biochemical genetics."

Trainee-candidates, who must be enrolled in an ACGME-approved clinical genetics specialty or medical biochemical genetics specialty residency program, are being asked to submit a joint application with their sponsoring institution to the ACMG Foundation for review.

Genzyme and the ACMG Foundation will support awardees with $75,000 during the fellowship year. The deadline to apply is August 15. More information is available, here.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.